Firstauthor [ref.no.] | Agent | Dosemg m−2 | Patientsn | RRu % | RRs % | RRr % | Grade 4 neutopenia % |
Ettinger 80 | Paclitaxel | 250 | 36 | 34 | 56 | ||
Kirsohung 81 | 43 | 53 | 56 | ||||
Hesketh 82 | Docetaxel | 100 | 43 | 25 | 58 | ||
Kelly 79 | Topoteca | 125 | 378 | 33 | 15–38 | 5 | 50–70 |
Huber 83 | 1.25 | 171 | 14 | 12 | |||
Kelly 79 | Irinoteca | 100 | 50 | 30–50 | NR | ||
Cormer 74 | Gemcitabe | 1000 | 29 | 27 | 18 | ||
Postmus 75 | Gemciabine | 1000 | 12 | 25 | NR | ||
Masters 86 | Gemcitabie | 1000 | 43 | 12 | 26 | ||
Kelly 79 | Virorelbine | 25–30 | 120 | 27 | 15 | 40–60 |
RRu, RRs, RRr: response rate in untreated relapsing previous sensitivepatients and in primarily refractory patients
NR: not reported